A25Early antiretroviral therapy favors post-treatment SIV control, which is associated with enhanced CD8+ T-cell antiviral activity against rebounding virus ' the pVISCONTI studyOn-demand oral abstract sessionHIV-1 controllers (including post-treatment controllers) and long-term non-progressors
A19Evaluation of HIV-1 reservoir size and broadly neutralizing antibody (bNAb) susceptibility in individuals who initiated ART during acute and chronic infectionOn-demand oral abstract sessionCharacterizing HIV/SIV reservoirs and rebounding virus
B80Robust SARS-CoV-2-specific serological and functional t-cell immunity in PLWHIVOn-demand oral abstract sessionImmune responses against SARS-CoV2 in PLWHIV
B30Rising substance use linked to STI and HCV in Thai MSM after acute HIV infectionOn-demand oral abstract sessionSubstance abuse (including opioid use disorder)
B13High HCV cure rates in C-FREE, first community-based study offering testing and treatment of viral hepatitis and HIV among people who use drugs and their partners in ThailandOn-demand oral abstract sessionViral hepatitis C
B13Reaching HCV micro-elimination in HIV/HCV co-infected individuals in the Netherlands: exploring remaining barriers to HCV treatmentOn-demand oral abstract sessionViral hepatitis C
B13Evaluation of the HCV cascade of care among people with HIV/hepatitis C co-infection in New South Wales, Australia: a data linkage studyOn-demand oral abstract sessionViral hepatitis C
B11Outcomes and incidence of TB among people living with HIV who received TB preventive therapy in UgandaOn-demand oral abstract sessionTuberculosis and other mycobacteria
B3The clinical effects of durably low CD4 counts while virologically suppressed among ART-initiating persons with HIV in Latin AmericaOn-demand oral abstract sessionDeterminants of HIV progression and disease control
B11Correlates associated with mortality among HIV-TB co-infected patients in Mumbai, IndiaOn-demand oral abstract sessionTuberculosis and other mycobacteria
741 - 750 of 870 items